Urolithiasis associated with topiramate

International Braz J Urol

Volumn 30, Issue 1, 2004, Pages 29-30

  Eggener, Scott ^a   Kim, Samuel C ^a   User, Herbert M ^a   Pazona, Joseph ^a   Nadler, Robert B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acids; Adverse effects; Anticonvulsants; Metabolism; Urolithiasis

Indexed keywords

ANTICONVULSIVE AGENT; APATITE; CARBONIC ACID; PHENOBARBITAL; RISPERIDONE; TOPIRAMATE; WEDDELLITE; WHEWELLITE;

ADULT; ARTICLE; CASE REPORT; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REGIMEN; DYSURIA; FLANK PAIN; HEMATURIA; HUMAN; HYDROURETER; INTRACTABLE EPILEPSY; MALE; URETER OBSTRUCTION; URETER STENT; URETEROPELVIC JUNCTION; URETEROSCOPY; UROLITHIASIS;

EID: 1642444798     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1677-55382004000100006     Document Type: Article

References (3)

1. Wasserstein AG, Rak I, Reife RA: Nephrolithiasis during treatment with topiramate. Epilepsia. 1995; 36 (suppl 3): 153.
2. Wasserstein AG, Rak I, Reife RA: Investigation of the mechanistic basis for topiramate-associated nephrolithiasis: Examination of urine and serum constituents. Epilepsia. 1995; 36 (suppl 3): 153.
3. Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE: Topiramate-induced nephrolithiasis. J Endourol. 2002; 16: 229-31.